Agilent Unifies CDMO Operations Under New Advanced Therapeutics Division — Agilent Technologies, Inc.

Event summary

Agilent launched Agilent Advanced Therapeutics on March 11, 2026, unifying CDMO capabilities across Canada and the U.S.
The new division integrates BIOVECTRA (Canada) and Nucleic Acid Solutions (Colorado) under one platform.
Services span oligonucleotides, microbial fermentation, complex chemistry, bioreagents, and cell line development.
Agilent reported $6.95 billion in revenue for fiscal year 2025, employing ~18,000 globally.

The big picture

Agilent's move reflects broader industry consolidation in the CDMO space, driven by demand for end-to-end therapeutic manufacturing solutions. The integration positions Agilent to capture a larger share of the growing advanced therapeutics market, though execution risks remain. With $6.95 billion in annual revenue, Agilent's scale could provide a competitive edge, but operational hurdles may slow near-term growth.

What we're watching

Integration Challenges: How Agilent will manage operational synergies between BIOVECTRA and Nucleic Acid Solutions.
Market Positioning: Whether the unified platform can compete with larger CDMO players like Lonza or Catalent.
Customer Retention: The pace at which Agilent converts existing clients into long-term partners under the new structure.